TABLE 1.

Baseline demographics of the 57 patients who started using opicapone per protocol and subgroups according to direct switch from etacapone or prior cessation of entacapone

	All patients starting opicapone (n = 57; 32 male, 25 female) mean (range)	Patients who switched from entacapone (n = 20; 12 male, 8 female) mean (range)	Patients who had previously stopped entacapone (n = 37; 20 male, 17 female) mean (range)	Baseline comparison between entacapone switchers and prior stoppersmean difference (SE)P value
PD duration (yr)	11.0 (2–26)	10.0 (3–19)	11.6 (2–26)	1.5 (1.4) P = 0.28
Age (yr)	64.0 (45–84)	61.5 (45–73)	65.4 (47–84)	3.9 (2.6) P = 0.14
l‐dopa dose (mg/day)		950 (400–2150)	857 (225–1800)	U = 265* P = 0.46
l‐dopa equivalent daily dose (mg/day)	1285 (475–2398)	1415 (782–2272)	1213 (475–2398)	U = 263* P = 0.07
l‐dopa frequency (doses/day)	6.2 (3–9)	6.2 (4–9)	6.3 (3–9)	NS
OFF time (hr/day)	5. 3 (1.5–12)	5.0 (2–8)	5.4 (1.5–12)	0.4 (0.75) P = 0.61
ON time after each l‐dopa dose (hr/dose)	2.0 (0.25–4)	2.1 (1.25–3.5)	2.0 (0.25–4)	0.1(2.3) P = 0.61

^aNon‐parametric comparisons were performed for comparisons of non‐normally distributed data.